Objective: To determine if increasing the hormone dose or eliminating the hormone-free interval improves key pharmacokinetic (PK) alterations caused by obesity during oral contraceptive (OC) use. Study design: Obese [body mass index (BMI)≥30 kg/m2], ovulatory, otherwise healthy, women received an OC containing 20mcg ethinyl estradiol (EE)/100mcg levonorgestrel (LNG) dosed cyclically (21 days active pills with 7-day placebo week)…